GH Research is taking its psychedelic 5-MeO-DMT public on the Nasdaq with an IPO valued at more than $100 million.

This week in psychedelic business: Mindset Pharma's new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”

HAVN VS. Mindmed - Whose Cluster Headache Treatment Is Better? Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our "This Week In Psychedelic Stocks" segment. In light of HAVN's recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore. HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind. Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020. The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms. DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. Full Disclosure: This video is for entertainment only and shouldn't be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) . https://havnlife.com/ CSE: HAVN | OTC: HAVLF | FRA: 5NP #HAVN #HAVNLifeSciences #Mindmed